Disclaimer: MercyIowaCityClinics.org is an independent editorial publication and is not affiliated with any hospital, clinic, or medical provider. GLP-3R is a research peptide — not approved for human consumption. These statements have not been evaluated by the FDA.
Peptide Sciences' Retatrutide: The Most Tested—But Also the Most Failed
Peptide Sciences has conducted more independent testing on retatrutide than any other vendor in the research peptide market—41 documented tests spanning June 2025 through July 2026. That volume alone might suggest confidence. But the MICC Review Team's analysis of Finnrick Analytics data reveals a troubling paradox: despite holding the #1 ranking by test volume, Peptide Sciences' GLP-3R product passes quality assurance only 51% of the time. Of 41 tests, 21 passed and 20 failed. This inconsistency, coupled with identity verification failures and purity shortfalls, suggests significant manufacturing or supply chain instability for this particular compound.
The Identity Crisis: Zero Milligrams Detected
The most serious red flag in Peptide Sciences' retatrutide testing record is repeated identity failures where samples contained 0 mg of detectable retatrutide—meaning some vials appear to have shipped with no active compound whatsoever. These are not marginal failures or minor concentration deviations. Identity verification exists to confirm that what the customer receives actually matches the labeled product. When a vial fails at 0 mg, it raises fundamental questions about quality control, raw material sourcing, and batch segregation protocols.
Identity failures of this magnitude suggest either contaminated raw materials, equipment cross-contamination, or a complete breakdown in manufacturing oversight. For a research peptide positioned as a triple-agonist targeting GLP-1R, GIPR, and GCGR receptors—and one based on Eli Lilly's clinical-stage retatrutide (LY3437943)—the inability to consistently deliver the labeled molecule is disqualifying for serious research applications. The MICC Review Team notes that Peptide Sciences performs substantially better on other products: semaglutide tests show 81% pass rates, and GHK-Cu reaches 92%. This suggests the retatrutide manufacturing or supply chain may be uniquely problematic, rather than a company-wide quality collapse.
Overfilling and Purity: Inconsistency in Both Directions
Beyond identity failures, Peptide Sciences' retatrutide batches have shown overfilling of +45% to +46% in some samples—meaning vials contained significantly more product than labeled. While overfilling might initially appear to benefit the customer, it indicates loss of manufacturing control. Over-delivering product while simultaneously shipping identity-failed vials suggests batches are not being properly verified before shipment.
On purity, test results cluster around 99.0% to 99.4%—adequate for many research applications, but repeatedly falling short of the 99.5%+ standard expected for pharmaceutical-grade peptides. The pattern is erratic. Purity when the compound is present is reasonable, but combined with identity failures and overfilling, the data paints a picture of batch-to-batch inconsistency. Post-shutdown testing in spring 2026 showed significant failures, followed by later recoveries, suggesting reactive rather than preventive quality management.
Finnrick's #1 Ranking: Volume, Not Validation
Peptide Sciences holds a Finnrick Analytics score of 56% for retatrutide and ranks #1 by test volume among 223 retatrutide vendors. This ranking is important to contextualize: it reflects the sheer number of tests conducted, not their quality outcomes. In fact, a 56% pass rate places the company in the lower-middle tier of vendor reliability. For comparison, Peptide Sciences' overall vendor rating across all products is 61%, ranking #241 of 274 vendors—a notably weak position in a crowded market.
The volume ranking creates a potential illusion of credibility. Customers may assume “most-tested” equals “best-tested.” The MICC Review Team's analysis suggests the opposite interpretation: Peptide Sciences' extensive testing may reflect not confidence but rather the necessity of iterative retesting after repeated failures. The 51% pass rate on retatrutide specifically indicates fundamental process issues that additional volume has not resolved.
Pricing and Customer Ratings: Premium Price, Mediocre Results
Peptide Sciences prices its GLP-3R at a median of $17.92 per milligram—a premium position in the research peptide market. At that price point, customers might reasonably expect 95%+ pass rates and zero identity failures. Instead, they are receiving a product with a 51% pass rate and documented instances of vials containing no detectable retatrutide.
Customer ratings on the platform stand at 4.3 stars across 12 reviews—respectable on the surface, but potentially inflated by customers who purchased before the extended Finnrick testing period revealed systematic failures. Public feedback data is limited, and the volume of reviews is small relative to test failures. The disconnect between customer satisfaction scores and objective Finnrick testing data suggests customers may lack visibility into the true failure rates documented by independent labs.
Clinical Context: Why Retatrutide Matters—and Why Quality Fails Matter More
Retatrutide is a synthetic 39-amino-acid triple-agonist designed to target three receptors: GLP-1R, GIPR, and GCGR. Eli Lilly's clinical retatrutide (LY3437943) is currently in Phase 3 trials with reported body weight reduction of 28-30% over 68-80 weeks—significantly higher than semaglutide (~15%) or tirzepatide (~22%). FDA approval of the pharmaceutical version is anticipated around 2027.
For researchers evaluating retatrutide as a research compound, the clinical efficacy profile is compelling—but it depends entirely on consistent, verified peptide chemistry. A sample that fails identity verification at 0 mg will produce zero data. Overfilled batches may skew dose-response curves. Purity below 99.5% may introduce contaminants that confound downstream analyses. In research applications, process failure directly translates to data failure.
Traceability Gaps and Batch-to-Batch Volatility
Finnrick's testing records indicate numerous samples lacking proper batch identification or traceability information. This is a procedural red flag that suggests inadequate documentation and quality systems. Without clear batch tracking, it becomes difficult to identify which manufacturing runs are problematic and which are acceptable—a prerequisite for systematic process improvement.
The erratic swing from spring 2026 failures to later recoveries further suggests reactive troubleshooting rather than systematic control. Legitimate manufacturers implement preventive quality systems designed to eliminate variation. Peptide Sciences' retatrutide profile suggests a company responding to test failures after the fact, rather than preventing them upstream.
Final Assessment: Proceed with Extreme Caution
The MICC Review Team's assessment is direct: Peptide Sciences' GLP-3R retatrutide is the most-tested retatrutide product on the market, but also the most failed. A 51% pass rate, combined with identity failures and overfilling, indicates manufacturing process issues that have not been resolved despite extensive testing. The vendor performs substantially better on other peptides (semaglutide 81%, GHK-Cu 92%), which suggests the retatrutide problems may be compound-specific—but that distinction offers little reassurance for researchers seeking reliable GLP-3R.
For serious research applications, Peptide Sciences' retatrutide represents a high-risk choice. The identity failures alone—vials containing 0 mg of detectable retatrutide—are disqualifying for any research requiring consistent, validated peptide chemistry. The inconsistent batch quality, overfilling, and purity shortfalls compound the concern. Researchers should either seek alternative vendors with higher pass rates on retatrutide or defer research until Eli Lilly's pharmaceutical-grade retatrutide becomes available through regulated channels.
Compare Other GLP-3R Triple-Agonist Vendors
This review is part of our ongoing evaluation of research-grade retatrutide (GLP-3R) vendors. For a complete picture, see how other suppliers compare:
- Our Sourced Peptides Glp-3R Review — ≥99% HPLC purity with batch-specific COA — among the more transparent vendors in this space
- the Amino Asylum retatrutide evaluation — Finnrick-rated 78% (#2 of 223 vendors) with mixed dosage results but consistent purity
- our Swole AF Labs GLP-3R review — UK-based vendor with no Finnrick-verified independent testing on record — transparency gaps noted
- Our Nationwide Peptides Glp-3R Review — Claims ≥99% purity with COA (HPLC/MS) and GMP synthesis — not yet Finnrick-verified
Each vendor review examines purity testing, dosage accuracy, pricing, and transparency — the factors that matter most for research-grade peptide procurement.
These statements have not been evaluated by the FDA. GLP-3R is a research peptide not intended for human consumption. Always consult a qualified healthcare provider before considering any research compounds.